Palvella Therapeutics Files 8-K
Ticker: PVLA · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1583648
| Field | Detail |
|---|---|
| Company | Palvella Therapeutics, Inc. (PVLA) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, financials, disclosure
TL;DR
Palvella Therapeutics (fka Pieris Pharma) filed an 8-K on Jan 13, 2025, mostly financial exhibits.
AI Summary
On January 13, 2025, Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update for the company, which is incorporated in Nevada and operates in the pharmaceutical preparations sector.
Why It Matters
This filing indicates a routine corporate update for Palvella Therapeutics, Inc., providing necessary disclosures to investors and the market.
Risk Assessment
Risk Level: low — The filing appears to be a standard disclosure of financial statements and exhibits, with no immediate indication of significant new risks or events.
Key Numbers
- 001-37471 — SEC File Number (Identifies the company's filing history with the SEC.)
- 30-0784346 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- PALVELLA THERAPEUTICS, INC. (company) — Registrant
- Pieris Pharmaceuticals, Inc. (company) — Former company name
- January 13, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 125 Strafford Ave , Suite 360 (address) — Principal executive offices
- Wayne, Pennsylvania 19087 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of January 13, 2025.
What was Palvella Therapeutics, Inc. formerly known as?
Palvella Therapeutics, Inc. was formerly known as Pieris Pharmaceuticals, Inc.
In which state is Palvella Therapeutics, Inc. incorporated?
Palvella Therapeutics, Inc. is incorporated in Nevada.
What is the business address of Palvella Therapeutics, Inc.?
The business address of Palvella Therapeutics, Inc. is 125 Strafford Ave, Suite 360, Wayne, Pennsylvania 19087.
What is the SIC code for Palvella Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Palvella Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-01-13 07:00:17
Key Financial Figures
- $0.001 — ge on which registered Common stock , $0.001 par value per share PVLA The Nasdaq
Filing Documents
- pirs20250113_8k.htm (8-K) — 27KB
- ex_764841.htm (EX-99.1) — 23KB
- slide01.jpg (GRAPHIC) — 181KB
- slide02.jpg (GRAPHIC) — 317KB
- slide03.jpg (GRAPHIC) — 229KB
- slide04.jpg (GRAPHIC) — 270KB
- slide05.jpg (GRAPHIC) — 219KB
- slide06.jpg (GRAPHIC) — 182KB
- slide07.jpg (GRAPHIC) — 122KB
- slide08.jpg (GRAPHIC) — 159KB
- slide09.jpg (GRAPHIC) — 164KB
- slide10.jpg (GRAPHIC) — 169KB
- slide11.jpg (GRAPHIC) — 186KB
- slide12.jpg (GRAPHIC) — 112KB
- slide13.jpg (GRAPHIC) — 200KB
- slide14.jpg (GRAPHIC) — 166KB
- slide15.jpg (GRAPHIC) — 175KB
- slide16.jpg (GRAPHIC) — 218KB
- slide17.jpg (GRAPHIC) — 189KB
- slide18.jpg (GRAPHIC) — 135KB
- slide19.jpg (GRAPHIC) — 207KB
- slide20.jpg (GRAPHIC) — 197KB
- slide21.jpg (GRAPHIC) — 191KB
- slide22.jpg (GRAPHIC) — 189KB
- slide23.jpg (GRAPHIC) — 123KB
- slide24.jpg (GRAPHIC) — 143KB
- slide25.jpg (GRAPHIC) — 246KB
- slide26.jpg (GRAPHIC) — 154KB
- slide27.jpg (GRAPHIC) — 151KB
- slide28.jpg (GRAPHIC) — 153KB
- slide29.jpg (GRAPHIC) — 155KB
- slide30.jpg (GRAPHIC) — 109KB
- slide31.jpg (GRAPHIC) — 190KB
- slide32.jpg (GRAPHIC) — 188KB
- slide33.jpg (GRAPHIC) — 119KB
- slide34.jpg (GRAPHIC) — 161KB
- slide35.jpg (GRAPHIC) — 231KB
- slide36.jpg (GRAPHIC) — 270KB
- slide37.jpg (GRAPHIC) — 102KB
- slide38.jpg (GRAPHIC) — 136KB
- 0001437749-25-000924.txt ( ) — 9568KB
- pvla-20250113.xsd (EX-101.SCH) — 3KB
- pvla-20250113_def.xml (EX-101.DEF) — 12KB
- pvla-20250113_lab.xml (EX-101.LAB) — 15KB
- pvla-20250113_pre.xml (EX-101.PRE) — 12KB
- pirs20250113_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On January 13, 2025, Palvella Therapeutics, Inc. (the " Company ") posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is attached hereto as Exhibit 99.1, and incorporated herein by reference. The information furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document 99.1 Corporate Presentation of Palvella Therapeutics, Inc., dated January 13, 2025* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) *Furnished herewith
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PALVELLA THERAPEUTICS, INC. Date: January 13, 2025 By: /s/ Matthew Korenberg Matthew Korenberg Chief Financial Officer